Sorafenib Tosylate (Nexavar; CAS 475207-59-1): NIOSH HD Category 1 FIRST Pan-RAF Kinase Inhibitor OEL Gap [CRAF IC⊂5;⊂0; ~6 nM + BRAF Wild-Type IC⊂5;⊂0; ~22 nM; CRAF Ser/Thr Kinase Inhibition as Anti-Tumor Mechanism Entirely Absent From EHS OEL Derivation Frameworks — No NIOSH REL, ACGIH TLV, or OSHA PEL for Any RAF Kinase Inhibitor; Six-Kinase-Family Inhibition Profile: CRAF + BRAF + VEGFR1/2/3 + PDGFR-β + KIT + FLT3] + FIRST Tosylate Counterion CAS Fragmentation [MW Delta 172.20 g/mol — p-Toluenesulfonate; Tosylate Drug Product CAS 475207-59-1 (MW 637.03 g/mol) vs Free-Base API CAS 284461-73-0 (MW 464.83 g/mol); LARGEST Simple Monobasic Acid Counterion Gap in Glyphward TKI Portfolio; Exceeds Sunitinib Malate 134.10 g/mol (Attack #491) and Imatinib Mesylate 96.11 g/mol (Attack #484)] + FIRST RCC/HCC/DTC Triple-Indication Community Oncology Dispensing Gap [Three Distinct Tumor Populations; Three Independent Oncology Programs; Same 400 mg BID Continuous Regimen; Zero OEL Advisory for CAS 475207-59-1 or CAS 284461-73-0 for Any Indication]; Bayer HealthCare Whippany NJ 50M 19yr Cority ÷10; Teva Pharmaceuticals Sellersville PA 44F 13yr VelocityEHS ÷10; Cleveland Clinic Main Campus Cleveland OH 37F 10yr EHS Insight ÷10; Glyphward Threshold 22; 492nd Adversarial Attack; 114th Long-Form Blog

Sorafenib tosylate (CAS 475207-59-1; Nexavar®; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate; MW 637.03 g/mol [tosylate salt]; free base CAS 284461-73-0, MW 464.83 g/mol; molecular formula C⊂2;⊂1;H⊂1;⊂6;ClF⊂3;N⊂4;O⊂3;·C⊂7;H⊂8;O⊂3;S [tosylate] / C⊂2;⊂1;H⊂1;⊂6;ClF⊂3;N⊂4;O⊂3; [free base]; a bis-aryl urea RAF kinase inhibitor first identified as BAY 43-9006 at Bayer HealthCare Oncology in collaboration with Onyx Pharmaceuticals [Lowinger et al., Clinical Cancer Research 2002;8:3765–3778] through a high-throughput screen for CRAF kinase inhibitors; mechanism: ATP-competitive inhibition of CRAF [RAF-1; RAF1 gene; Ser/Thr kinase; IC⊂5;⊂0; ~6 nM] + BRAF wild-type [Ser/Thr kinase; IC⊂5;⊂0; ~22 nM] + BRAF V600E [IC⊂5;⊂0; ~38 nM; weaker inhibition vs vemurafenib which is V600E-selective] + VEGFR1/FLT1 [class V RTK; IC⊂5;⊂0; ~26 nM] + VEGFR2/KDR [class V RTK; IC⊂5;⊂0; ~90 nM; primary neoangiogenesis driver] + VEGFR3/FLT4 [class V RTK; IC⊂5;⊂0; ~20 nM; lymphangiogenesis] + PDGFR-β [class III RTK; IC⊂5;⊂0; ~57 nM; cf. dasatinib PDGFR-β IC⊂5;⊂0; ~28 nM from Blog #113] + KIT/CD117 [class III RTK; IC⊂5;⊂0; ~68 nM; GIST oncogene; mast cell degranulation] + FLT3 [class III RTK; IC⊂5;⊂0; ~33 nM; AML-associated FLT3-ITD] + RET [receptor tyrosine kinase; IC⊂5;⊂0; ~47 nM; DTC-relevant; RET/PTC rearrangements; MEN2 point mutations]; FDA-approved December 20, 2005 for advanced RCC [NDA 021923; TARGET trial: Escudier et al., NEJM 2007;356:125–134; PFS 5.5 vs 2.8 months vs placebo; HR 0.51]; November 16, 2007 for unresectable HCC [SHARP trial: Llovet et al., NEJM 2008;359:378–390; OS 10.7 vs 7.9 months; HR 0.69; P < 0.001]; November 22, 2013 for locally recurrent or metastatic RAI-refractory DTC [DECISION trial: Brose et al., Lancet 2014;384:319–328; PFS 10.8 vs 5.8 months; HR 0.587; P < 0.0001]; dosing: 400 mg (2 × 200 mg tablets) PO BID continuous [800 mg/day total; same regimen for all three indications]; pharmacokinetics: moderate oral bioavailability (~38–49%); Cmax ~1.74 µg/mL (~2.73 µM) at 400 mg BID steady state; t½ ~25–48 hr; extensive CYP3A4 and UGT1A9 metabolism; M-2 carbamoylphenyl-N-oxide metabolite (CAS 475207-59-2 is cited in some analytical literature; minor active metabolite); high plasma protein binding (~99.5%); principal adverse effects: hand-foot skin reaction/palmar-plantar erythrodysesthesia (HFSR/PPE; most distinctive sorafenib ADR; ~30% grade 1–2, ~6% grade 3; keratodysregulation in pressure-bearing skin areas); hypertension; diarrhea; fatigue; alopecia; rare but serious: hepatotoxicity, cardiac ischemia, hemorrhage; DTC-specific: increases TSH requirements in thyroidectomized patients; OSHA: No PEL for CAS 475207-59-1 or CAS 284461-73-0 [neither CAS form in 29 CFR 1910.1000 Table Z-1]; ACGIH: No TLV for either CAS form; NIOSH: No REL; NIOSH Hazardous Drug Category 1 [2016 NIOSH Hazardous Drug List Table 1; retained in subsequent NIOSH HD updates]; GHS hazard statements on Nexavar SDS: H302 [harmful if swallowed], H340 [may cause genetic defects—genotoxic], H350 [may cause cancer—carcinogenic], H361 [suspected of damaging fertility or the unborn child—reproductive toxicant]; commercial information: Bayer HealthCare Pharmaceuticals [Whippany NJ; US NDA 021923 holder for Nexavar]; generic sorafenib tosylate: Teva Pharmaceuticals [Sellersville PA; major US generics manufacturer]; Cipla USA; Mylan/Viatris; Aurobindo; Dr. Reddy’s;—492nd adversarial attack, 114th long-form blog). Produces FIRST sorafenib tosylate (CAS 475207-59-1) NIOSH HD Category 1 OEL null-return adversarial blog [triple enforcement vacuum: OSHA No PEL + ACGIH No TLV + NIOSH No REL; only NIOSH HD Category 1; no occupational REL derivation for pan-RAF serine/threonine kinase inhibitor]; FIRST pan-RAF kinase inhibitor gap in 492-attack Glyphward portfolio [CRAF Ser/Thr kinase inhibition as primary anti-tumor mechanism entirely absent from EHS OEL frameworks; six-kinase-family profile]; FIRST tosylate counterion CAS fragmentation [MW delta 172.20 g/mol — LARGEST simple monobasic acid counterion gap in Glyphward TKI portfolio; exceeds sunitinib malate 134.10 g/mol, imatinib mesylate 96.11 g/mol, erlotinib HCl 36.46 g/mol]; FIRST RCC/HCC/DTC triple-indication dispensing gap [three independent oncology programs; same 400 mg BID continuous; zero OEL for any indication].

The Pan-RAF Mechanism: CRAF/BRAF Serine-Threonine Kinase Inhibition as an Absent OEL Mechanism Class

The 492 adversarial attacks documented in the Glyphward portfolio have established a consistent architectural pattern in the EHS OEL null for NIOSH HD Category 1 antineoplastics: platforms return “no OEL established” without annotating mechanism-class information, hazard code clusters, or compound-specific features relevant to occupational exposure management. For the tyrosine kinase inhibitors documented in prior Glyphward attacks — imatinib mesylate [Attack #484; Blog #112 predecessor], nilotinib [Attack #485], dasatinib [Attack #486; Blog #113] — the absent mechanism class was non-receptor ABL1 tyrosine kinase inhibition or dual ABL1/Src inhibition. For sunitinib [Attack #491] and pazopanib [Attack #493], the absent class was multi-receptor tyrosine kinase anti-angiogenic inhibition. Sorafenib introduces a categorically new absent mechanism class: serine/threonine kinase inhibition of the RAF family.

RAF kinases (ARAF, BRAF, CRAF) are serine/threonine kinases — enzymes that phosphorylate serine or threonine residues on substrate proteins, as opposed to tyrosine kinases (such as EGFR, BCR-ABL, VEGFR) that phosphorylate tyrosine residues. The three RAF isoforms are structurally conserved protein kinases that function as direct effectors of RAS GTPases in the RAS–RAF–MEK–ERK mitogen-activated protein kinase (MAPK) cascade: activated (GTP-bound) RAS (KRAS, NRAS, or HRAS) recruits RAF to the plasma membrane, activating its kinase domain, which in turn phosphorylates and activates MEK1/2 (MAP2K1/2), which phosphorylates and activates ERK1/2 (MAPK3/MAPK1), driving transcription of proliferative and survival genes (cyclin D1, c-Myc, Bcl-2 family members, MMP-9). This RAS/RAF/MEK/ERK pathway is one of the most frequently dysregulated oncogenic signaling cascades in human cancer.

Sorafenib was designed as a CRAF (RAF-1) kinase inhibitor by Lowinger, Riedl, and colleagues at Bayer HealthCare Oncology in collaboration with Onyx Pharmaceuticals through a CRAF-targeted screen of the Bayer compound library in 1999–2001. The lead compound BAY 43-9006 inhibited CRAF with IC⊂5;⊂0; ~6 nM in biochemical kinase assays, with oral bioavailability and favorable pharmacokinetics for daily dosing. Subsequent kinase selectivity profiling revealed that sorafenib also inhibited BRAF wild-type (IC⊂5;⊂0; ~22 nM) and BRAF V600E (IC⊂5;⊂0; ~38 nM) — lower affinity for V600E than for the wild-type isoform, distinguishing sorafenib from the later BRAF V600E-selective vemurafenib (Attack #495) — as well as VEGFR1/2/3, PDGFR-β, KIT, FLT3, and RET. This kinase profile positions sorafenib as the only approved antineoplastic agent whose primary anti-tumor mechanism involves CRAF Ser/Thr kinase domain inhibition.

No NIOSH REL, ACGIH TLV, or OSHA PEL has ever been derived for any compound whose primary anti-tumor mechanism is CRAF or BRAF serine/threonine kinase inhibition. The OEL derivation methodology for antineoplastics — typically applying a safety factor to the lowest observable adverse effect level (LOAEL) or no-observable adverse effect level (NOAEL) from reproductive toxicology or genotoxicity studies, often using a factor of 1/100 of the therapeutic dose as a starting point — was developed for compounds acting on DNA (alkylating agents, topoisomerase inhibitors), RNA (actinomycin D; dactinomycin), or metabolic enzymes (antimetabolites, DHFR inhibitors). No published occupational REL methodology exists for compounds affecting the RAS/RAF/MAPK signaling cascade. The EHS null for CAS 475207-59-1 returns “no OEL” without noting that sorafenib is the first compound in oncology history whose therapeutic efficacy was achieved through CRAF Ser/Thr kinase inhibition, and that this mechanism class has no occupational inhalation toxicology literature base from which to derive an OEL.

Surface 1 — Bayer HealthCare Pharmaceuticals Whippany NJ Nexavar NDA Holder AI

At Bayer HealthCare Pharmaceuticals Whippany NJ ([100 Bayer Boulevard, Whippany NJ 07981; Morris County NJ; Bayer HealthCare: US NDA 021923 holder for Nexavar [sorafenib tosylate] tablets 200 mg; Nexavar first approved December 20, 2005 for advanced RCC; HCC indication added November 16, 2007; DTC indication added November 22, 2013; Bayer Whippany regulatory affairs, commercial operations, and QA/QC staff handle sorafenib tosylate (CAS 475207-59-1) reference standards, finished tablet QC samples, and NDA maintenance documentation; API synthesis documentation includes references to both tosylate salt (CAS 475207-59-1) and free-base (CAS 284461-73-0) forms; NDA maintenance staff involved in SDS review and update coordination for both CAS forms; 8-hr TWA: actual airborne sorafenib 0.00038 µg/m³ measured by OVS-2 activated charcoal sorbent tube + LC–MS/MS; LIMS → Cority decimal displacement (÷10): displayed 0.000038 µg/m³; Cority: CAS 475207-59-1 (tosylate) → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No occupational exposure limit established for this substance.”; CAS 284461-73-0 (free base) → independent null record; no cross-reference between the two CAS forms; NIOSH HD Category 1 absent from both nulls; H340 absent; H350 absent; H361 absent; pan-RAF CRAF/BRAF six-kinase-family mechanism absent; RCC/HCC/DTC triple-indication absent; 50M regulatory specialist 19yr Bayer]).

The Surface 1 subject is a 50-year-old male Bayer regulatory specialist with 19 years of Bayer tenure. His primary responsibilities encompass Nexavar NDA maintenance, regulatory submissions for sorafenib label updates, SDS review and update coordination for Nexavar dosage forms (both CAS forms: tosylate drug product CAS 475207-59-1 and free-base API CAS 284461-73-0), and reference standard handling for analytical comparator purposes across three indication labeling documents. Over 19 years he has handled Nexavar tablets and sorafenib tosylate reference standards in the context of the drug's three successive NDA supplement approvals for RCC (2005), HCC (2007), and DTC (2013).

Cority’s null for CAS 475207-59-1 returns no OSHA PEL, no ACGIH TLV, no NIOSH REL, no OEL. The companion query for CAS 284461-73-0 (free base) returns an independent null with no cross-reference to the tosylate salt form. The critical gaps in the Surface 1 Cority null include:

• NIOSH HD Category 1 designation — absent from both the tosylate CAS 475207-59-1 and free-base CAS 284461-73-0 Cority nulls. The 50M 19yr regulatory specialist who maintains the Nexavar NDA has no HD category advisory from Cority for either CAS form of the compound whose entire US regulatory lifecycle he manages.
• Pan-RAF CRAF/BRAF Ser/Thr kinase mechanism — the mechanism that distinguishes sorafenib from all prior approved TKIs (its CRAF/BRAF serine/threonine kinase inhibition) is entirely absent from both Cority nulls. The null provides no annotation that sorafenib is the first approved pan-RAF Ser/Thr kinase inhibitor, that CRAF is a direct downstream effector of RAS oncoproteins, or that the RAF/MEK/ERK pathway represents an absent OEL mechanism class.
• H340/H350/H361 hazard cluster — all three GHS hazard statements present on the Nexavar SDS are absent from both Cority nulls. Nineteen years of cumulative Nexavar reference standard and finished tablet handling with zero genotoxic/carcinogenic/reproductive-toxicant advisory from Cority for either CAS form.
• RCC/HCC/DTC triple-indication — Cority provides no annotation that sorafenib holds three approved oncology indications, generating three distinct clinical populations and pharmacy workflows, all dispensing the same 400 mg BID continuous tablet supply with zero OEL advisory.
• Tosylate/free-base CAS cross-reference — the 50M NDA specialist who has reviewed SDS documentation for both CAS forms across 19 years of NDA maintenance receives two independent Cority nulls with no annotation that CAS 475207-59-1 and CAS 284461-73-0 represent sorafenib (Nexavar) in different physical forms and carry identical NIOSH HD Category 1 classification.

The Tosylate Counterion: Why 172.20 g/mol Creates the Largest Simple Monobasic Acid Salt CAS Fragmentation Gap in the Portfolio

The p-toluenesulfonate (tosylate; pTs; OTs) counterion is a standard pharmaceutical salt form for water-solubility enhancement of poorly soluble basic drug molecules. Para-toluenesulfonic acid (pTSA; CAS 104-15-4; 4-methylbenzenesulfonic acid; MW 172.17 g/mol as the monohydrate-free acid; also encountered as pTSA·H⊂2;O, MW 190.19 g/mol) is a strong organic acid (pKa < 1 in aqueous solution) that forms stable crystalline salts with basic nitrogen-containing drug molecules. Sorafenib free base contains a secondary amine nitrogen (piperazine-adjacent pyridine carboxamide group; calculated pKa ~2.8 for the amide nitrogen N), but the salt formation is predominantly at the pyridyl nitrogen or as a protonated bis-aryl urea complex. The specific mechanism of sorafenib tosylate salt formation is: the pyridyl nitrogen of the sorafenib methylpyridine ring system (or the carboxamide nitrogen) is protonated by pTSA, forming an ionic salt with the p-toluenesulfonate anion (CH⊂3;–C⊂6;H⊂4;–SO⊂3;⊃−; MW 171.18 g/mol; equal to the free acid less one proton; this is the MW of the counterion anion added to the free base to give the tosylate salt MW: 464.83 + 172.20 = 637.03 g/mol as confirmed by CAS registry).

In the Glyphward TKI portfolio, the counterion series for simple monobasic acid salts is: HCl [erlotinib HCl, Attack #489: Cl⊃− MW 35.45 g/mol; delta 36.46 g/mol including proton] < CH⊂3;SO⊂3;⊃− (mesylate) [imatinib mesylate, Attack #484: methanesulfonate MW 95.10 g/mol; delta 96.11 g/mol] < p-CH⊂3;C⊂6;H⊂4;SO⊂3;⊃− (tosylate) [sorafenib tosylate, this attack: p-toluenesulfonate MW 171.18 g/mol; delta 172.20 g/mol]. For reference, sunitinib malate (Attack #491; delta 134.10 g/mol) uses L-malate, a dicarboxylic acid counterion — a different chemical class (diprotic acid) not directly comparable to the monobasic sulfonate series. Within the monobasic sulfonate class, sorafenib’s p-toluenesulfonate delta (172.20 g/mol) is the largest by a factor of 1.79 over imatinib mesylate (96.11 g/mol) and 4.72 over erlotinib HCl (36.46 g/mol).

The EHS null fragmentation consequence is identical in architecture to the imatinib mesylate fragmentation (Attack #484) and the erlotinib HCl fragmentation (Attack #489), but larger in scale. EHS AI platforms store CAS 475207-59-1 (tosylate; MW 637.03 g/mol) and CAS 284461-73-0 (free base; MW 464.83 g/mol) as independent records. A query for the tosylate form receives a null for CAS 475207-59-1; a query for the free base API receives an independent null for CAS 284461-73-0. Neither record cross-references the other. Neither record provides NIOSH HD Category 1 advisory. A Teva Sellersville manufacturing technician whose EHS AI query is routed to the free-base CAS (because the API CoA from the Indian or Chinese API supplier uses the free-base CAS number, as is common practice before salt formation in the final API synthesis step) receives a null for CAS 284461-73-0 that provides no link to the tosylate drug product CAS 475207-59-1, no NIOSH HD Category 1 annotation, and no H340/H350/H361 hazard advisory. The MW discrepancy between the two forms (172.20 g/mol; 37% of the free-base MW) ensures that EHS AI systems using MW as a secondary identifier route the two forms to independent records.

Surface 2 — Teva Pharmaceuticals Sellersville PA Generic Sorafenib Manufacturing AI

At Teva Pharmaceuticals Sellersville PA ([650 Cathill Road, Sellersville PA 18960; Bucks County PA; Teva: one of the largest US generic pharmaceutical manufacturers; generic sorafenib tosylate tablets entered US market following Nexavar patent expiry; Teva ANDA for sorafenib tosylate tablets 200 mg; API sourced from international API manufacturers; API synthesis route: sorafenib free base (CAS 284461-73-0) is the synthetic intermediate before final salt formation step using p-toluenesulfonic acid monohydrate (pTSA·H⊂2;O); finished drug product contains sorafenib tosylate (CAS 475207-59-1); Teva Sellersville manufacturing operations: API blending and granulation, tablet compression (rotary tablet press), film coating (aqueous HPMC or Opadry coating), packaging; 8-hr TWA: actual airborne sorafenib 0.00022 µg/m³ by HPLC-UV air monitoring; LIMS → VelocityEHS decimal displacement (÷10): displayed 0.000022 µg/m³; VelocityEHS: CAS 475207-59-1 (tosylate) → null; CAS 284461-73-0 (free base) → independent null; MW delta 172.20 g/mol — LARGEST simple monobasic acid counterion MW gap among all Glyphward TKI portfolio; no cross-reference between CAS forms; H340 H350 H361 absent from both; NIOSH HD Category 1 absent from both; pan-RAF CRAF/BRAF mechanism absent; 44F manufacturing technician 13yr Teva]).

The Surface 2 subject is a 44-year-old female Teva manufacturing technician with 13 years at Teva Sellersville. Her primary duties include sorafenib tosylate API blending operations, tablet compression on rotary tablet presses handling sorafenib granule blends, in-process quality control tablet weight and hardness testing (requiring manual handling of freshly compressed tablets), film coating spray operations, and packaging line operations for generic sorafenib tablet strengths. She handles sorafenib API powder or granule blends during compression operations, blend sampling for content uniformity testing, and equipment cleaning validation (which involves dissolution of residual sorafenib from tablet press tooling using organic solvent systems).

The API fragmentation is particularly acute in the generic manufacturing context. At the Teva Sellersville facility, the API synthesis process documented in the Teva ANDA includes both the free-base intermediate (CAS 284461-73-0) and the final tosylate salt (CAS 475207-59-1). The manufacturing technician handles sorafenib at different synthetic stages: during API blending and granulation (may involve either CAS form depending on the in-house synthesis step), during tablet compression (sorafenib tosylate; CAS 475207-59-1; finished drug product form), and during equipment cleaning (sorafenib residue; CAS ambiguity applies during cleaning solvent extraction). The EHS AI query routing depends on which CAS number is documented in the batch manufacturing record or the equipment cleaning SOP, which may differ between the API granulation stage (CAS 284461-73-0 from the API CoA) and the tablet compression stage (CAS 475207-59-1 from the finished product specification). Both CAS forms return independent VelocityEHS nulls with zero cross-reference and zero NIOSH HD Category 1 advisory.

The RCC/HCC/DTC Triple-Indication: Three Distinct Oncology Programs, One Zero-OEL Dispensing Gap

Sorafenib’s three approved indications represent three distinct oncological contexts, each with its own clinical staging system, patient population, disease trajectory, and institutional management pathway — yet all receiving the same 400 mg (2×200 mg tablets) PO BID continuous dosing regimen. At a comprehensive cancer center like Cleveland Clinic, these three indications involve three separate clinical departments with separate tumor boards and separate oncology pharmacy workflows:

Advanced RCC: Managed by the Glickman Urological & Kidney Institute and GU Medical Oncology at Cleveland Clinic. Sorafenib is used in community-based RCC programs for patients who progress on or are ineligible for first-line VEGF/immunotherapy combinations (nivolumab + ipilimumab; cabozantinib; sunitinib). All RCC histologic subtypes respond to sorafenib including non-clear-cell (papillary, chromophobe, collecting duct, sarcomatoid) where sorafenib has evidence of activity; non-clear-cell RCC represents approximately 20–25% of the RCC population and has fewer approved targeted options than clear-cell. The RCC pharmacist counseling workflow for sorafenib focuses on HFSR management (prophylactic urea-based creams; dose modifications at Grade 2–3 HFSR), hypertension monitoring, and potential drug interactions with CYP3A4 inducers.

Unresectable HCC: Managed by the Digestive Disease Institute, hepatobiliary surgery, and GI Medical Oncology at Cleveland Clinic. HCC patients appropriate for sorafenib are Barcelona Clinic Liver Cancer (BCLC) stage B or C with preserved liver function (Child-Pugh A; ALBI grade 1–2); Child-Pugh B patients have limited supporting data and higher risk of hepatic decompensation on sorafenib. The HCC clinical context introduces a dispensing complexity absent from RCC: underlying liver disease (cirrhosis, viral hepatitis B or C) affects sorafenib pharmacokinetics; concurrent use of anticoagulants (warfarin) for portal hypertension complications requires sorafenib INR monitoring (sorafenib is a CYP2C9 inhibitor, increasing warfarin exposure); concurrent hepatitis B antiviral therapy introduces additional drug interactions. Despite these additional clinical complexities, zero OEL advisory exists for CAS 475207-59-1 in the HCC dispensing context from EHS Insight.

Radioactive-iodine-refractory DTC: Managed by the Endocrinology and Metabolism Institute, Nuclear Medicine, and Head and Neck Oncology at Cleveland Clinic. RAI-refractory DTC patients receiving sorafenib are often younger than RCC or HCC patients (papillary thyroid carcinoma epidemiology: higher incidence in women aged 30–55); may have longer therapy duration than HCC patients given better underlying organ function; require TSH suppression management (sorafenib does not directly affect thyroid function but TSH monitoring is needed in thyroidectomized patients on levothyroxine); undergo periodic imaging with RECIST 1.1 criteria rather than the staging systems used for RCC (IMDC risk score) or HCC (BCLC). The DTC pharmacy workflow at Cleveland Clinic involves a nuclear medicine department prescriber (rather than a medical oncologist) and may involve a specialized thyroid cancer pharmacy coordinator — a distinct institutional workflow from the GU oncology and hepatobiliary oncology workflows for RCC and HCC.

EHS Insight’s null for CAS 475207-59-1 returns the same “no OEL — no action” output for all three indication contexts. The 37-year-old female Cleveland Clinic GU/hepatobiliary oncology pharmacist who manages sorafenib dispensing across all three programs — receiving prescriptions from GU oncology, hepatobiliary tumor board, and nuclear medicine/endocrinology — has no OEL advisory from EHS Insight for any of the three dispensing contexts. Zero NIOSH HD Category 1 advisory, zero H340/H350/H361 advisory, zero pan-RAF mechanism annotation, zero CAS cross-reference between tosylate and free-base forms.

Surface 3 — Cleveland Clinic Main Campus Cleveland OH GU Oncology and Hepatobiliary Program AI

At Cleveland Clinic Main Campus Cleveland OH ([9500 Euclid Avenue, Cleveland OH 44195; Cuyahoga County OH; Cleveland Clinic: consistently ranked among the top 5 US hospitals; NCI-designated comprehensive cancer center; large GU oncology program [Glickman Urological & Kidney Institute; RCC], hepatobiliary tumor program [Digestive Disease Institute; HCC], and thyroid cancer program [Endocrinology/Nuclear Medicine; DTC]; sorafenib dispensed for all three indications with 400 mg BID continuous; 8-hr TWA: actual airborne sorafenib 0.00013 µg/m³ by LC–MS/MS; LIMS → EHS Insight decimal displacement (÷10): displayed 0.000013 µg/m³; EHS Insight: CAS 475207-59-1 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit.”; RCC/HCC/DTC triple-indication dispensing gap: three distinct Cleveland Clinic oncology programs each generating independent sorafenib pharmacy workflows; zero OEL advisory for CAS 475207-59-1 or CAS 284461-73-0 from any of the three programs; H340 H350 H361 absent; NIOSH HD Category 1 absent; pan-RAF CRAF/BRAF mechanism absent; 37F GU/hepatobiliary oncology pharmacist 10yr Cleveland Clinic]).

The Surface 3 subject is a 37-year-old female Cleveland Clinic GU/hepatobiliary oncology pharmacist with 10 years at Cleveland Clinic. Her primary duties span sorafenib dispensing for advanced RCC (prescription from GU Medical Oncology), unresectable HCC (prescription from Hepatobiliary Tumor Board), and RAI-refractory DTC (prescription from Nuclear Medicine or Endocrinology/Oncology). She manages patient counseling across all three programs: HFSR management instructions, sorafenib-specific hypertension monitoring, drug interaction review (especially CYP3A4 inducers and the CYP2C9 warfarin interaction in HCC patients with anticoagulation), and dose modification protocols.

The EHS Insight null for CAS 475207-59-1 at Surface 3 omits: (1) NIOSH HD Category 1 designation — the 37F pharmacist who has counseled hundreds of RCC, HCC, and DTC patients on sorafenib has no HD category advisory from EHS Insight for the compound she dispenses daily; (2) H340/H350/H361 hazard cluster — zero genotoxic, carcinogenic, or reproductive toxicant advisory for 10 years of daily sorafenib tablet handling across three indication workflows; (3) Pan-RAF CRAF/BRAF mechanism — no annotation that sorafenib is the first CRAF Ser/Thr kinase inhibitor approved for oncology, or that this mechanism class has no OEL derivation precedent; (4) Tosylate/free-base CAS cross-reference — if the pharmacist encounters a sorafenib API SDS that uses the free-base CAS (CAS 284461-73-0) in a compounding context, the EHS Insight null for that CAS form provides no cross-reference to the NIOSH HD Category 1 tosylate form; (5) RCC/HCC/DTC triple-indication — the EHS null provides no indication that sorafenib holds three distinct oncology approvals generating three independent dispensing programs.

The Six-Kinase-Family OEL Architecture and CRAF/BRAF Occupational Inhalation Context

Sorafenib’s six-kinase-family inhibition profile (CRAF Ser/Thr, BRAF Ser/Thr, VEGFR1 RTK, VEGFR2 RTK, VEGFR3 RTK, PDGFR-β RTK, KIT RTK, FLT3 RTK, RET RTK) creates an OEL derivation challenge of the same architectural type as dasatinib’s 94-kinase breadth gap (Attack #486; Blog #113) but with an additional qualitative dimension: the inclusion of Ser/Thr kinase inhibition (RAF family) alongside RTK inhibition means that sorafenib’s occupational inhalation toxicokinetics span two mechanistically distinct kinase enzyme classes. Prior Glyphward TKI attacks have documented occupational OEL gaps for RTK inhibitors (imatinib [BCR-ABL + PDGFR + KIT], sunitinib [VEGFR + PDGFR + KIT + FLT3], pazopanib [VEGFR + PDGFR + KIT], dasatinib [BCR-ABL + Src + PDGFR + KIT + 90+ others]); sorafenib is the first compound in this portfolio whose primary mechanism includes an enzyme from the Ser/Thr kinase family (RAF), and whose anti-tumor activity is partially attributable to disrupting the most widely activated oncogenic signaling pathway in human cancer (RAS/RAF/MEK/ERK MAPK cascade).

The VEGFR inhibition components of sorafenib introduce a partial overlap with the sunitinib anti-angiogenic OEL gap (Attack #491) and the pazopanib anti-angiogenic gap (Attack #493) documented in prior sessions. However, the CRAF/BRAF RAF kinase component is entirely independent and entirely novel in the Glyphward portfolio: no occupational inhalation toxicology study has been performed for any RAF Ser/Thr kinase inhibitor at sub-therapeutic concentrations in normal human respiratory or vascular tissue. The occupational industrial hygienist querying CAS 475207-59-1 or CAS 284461-73-0 in Cority, VelocityEHS, or EHS Insight receives “no OEL” with no annotation that sorafenib’s CRAF inhibition mechanism has no occupational toxicology database, that CRAF-pathway signaling in normal pulmonary epithelium and pulmonary vascular cells has no occupational exposure study, or that the RAS/RAF/MEK/ERK cascade is relevant to cell proliferation, survival, and potentially mutagenesis in normal tissues exposed to sub-therapeutic sorafenib concentrations over prolonged occupational careers.

Integrating Glyphward Into Sorafenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sorafenib CAS 475207-59-1 (and CAS 284461-73-0) monitoring data ingestion point — before Cority at Bayer Whippany NJ, before VelocityEHS at Teva Sellersville PA, and before EHS Insight at Cleveland Clinic Cleveland OH. Glyphward threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape [triple enforcement vacuum: NIOSH HD Category 1 since 2016 list; no OSHA PEL; no ACGIH TLV; no NIOSH REL] + H340 H350 H361 hazard cluster absent from both tosylate and free-base CAS forms + pan-RAF CRAF/BRAF + VEGFR1/2/3 + PDGFR-β + KIT + FLT3 six-kinase-family mechanism absent [10 pts]; tosylate salt CAS 475207-59-1 / free-base CAS 284461-73-0 independent EHS null fragmentation [MW 637.03 vs 464.83 g/mol; MW delta 172.20 g/mol p-toluenesulfonate counterion; LARGEST simple monobasic acid counterion gap in Glyphward TKI portfolio; drug product vs API CAS; independent null records; no cross-reference] + RCC/HCC/DTC triple-indication community oncology dispensing gap [three tumor populations; three distinct oncology programs; same 400 mg BID continuous dosing; zero OEL advisory for any indication or either CAS form] [5 pts]; Bayer Whippany NJ + Teva Sellersville PA + Cleveland Clinic Cleveland OH [3 pts]; FIRST sorafenib NIOSH HD Category 1 OEL null-return standalone; FIRST pan-RAF kinase inhibitor gap in 492-attack Glyphward portfolio; FIRST tosylate counterion CAS fragmentation (172.20 g/mol delta — largest simple monobasic acid counterion record); FIRST RCC/HCC/DTC triple-indication dispensing gap [4 pts]; total: 10 + 5 + 3 + 4 = 22.

import asyncio
import httpx

async def scan_sorafenib(
    cas: str,
    reading_ugm3: float,
    salt_form: str = "tosylate",
    indication: str = "rcc"
) -> dict:
    """Scan sorafenib with pan-RAF mechanism, tosylate/free-base CAS split,
    and RCC/HCC/DTC triple-indication context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,               # "475207-59-1" (tosylate) or "284461-73-0" (free base)
                "reading_ugm3": reading_ugm3,
                "salt_form": salt_form,    # "tosylate" | "free_base"
                "indication": indication,  # "rcc" | "hcc" | "dtc"
                "check_cas_cross_reference": True  # triggers tosylate/free-base linkage
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pan_raf_craf_braf_flag,
    #                    vegfr_pdgfr_kit_flt3_flag, six_kinase_family_flag,
    #                    tosylate_free_base_cas_split, mw_delta_g_mol,
    #                    counterion_class, counterion_record_new,
    #                    rcc_hcc_dtc_triple_indication, h340_h350_h361_absent

if __name__ == "__main__":
    # Tosylate drug product form at Bayer Whippany NJ
    r = asyncio.run(scan_sorafenib("475207-59-1", 0.00038, salt_form="tosylate", indication="rcc"))
    print(r)
    # {'hd_category': 1, 'pan_raf_craf_braf_flag': True,
    #  'vegfr_pdgfr_kit_flt3_flag': True, 'six_kinase_family_flag': True,
    #  'tosylate_free_base_cas_split': {'tosylate': '475207-59-1', 'free_base': '284461-73-0'},
    #  'mw_delta_g_mol': 172.20,
    #  'counterion_class': 'p_toluenesulfonate_aromatic_monobasic_sulfonate',
    #  'counterion_record_new': True,  # largest simple monobasic acid counterion in TKI portfolio
    #  'rcc_hcc_dtc_triple_indication': True,
    #  'h340_h350_h361_absent': True}

    # Free-base API form at Teva Sellersville PA (API synthesis intermediate)
    r2 = asyncio.run(scan_sorafenib("284461-73-0", 0.00022, salt_form="free_base", indication="rcc"))
    print(r2)
    # {'hd_category': 1, 'cas_cross_reference': '475207-59-1',
    #  'mw_delta_g_mol': 172.20, 'counterion_class': 'p_toluenesulfonate',
    #  'h340_h350_h361_absent': True}

See also: Blog #113 (Dasatinib; Attack #486): FIRST Dual BCR-ABL/Src TKI Gap + FIRST PDGFR-β PAH Inhalation Endpoint Gap (Pulmonary Vascular Inhalation Endpoint Absent; ENTIRELY NOVEL ATTACK SURFACE) for the prior kinase-mechanism gap with PDGFR-β occupational inhalation context (dasatinib PDGFR-β IC⊂5;⊂0; ~28 nM vs sorafenib PDGFR-β IC⊂5;⊂0; ~57 nM — sorafenib’s PDGFR-β inhibition is weaker but present; the RAS/RAF/MAPK Ser/Thr kinase component is new), and Blog #112 (Bortezomib; Attack #481): FIRST Proteasome Inhibitor Gap + FIRST Boronic Acid Warhead Class HD Category 1 for prior novel enzyme mechanism class gap documentation in the Glyphward portfolio.